Neurosciences articles for Netherlands

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 83

Article ‘Count’ for Neurosciences.

Journal Count Share
1 0.11
Action Collaborative on Traumatic Brain Injury Care: Adapted Clinical Practice Guideline 0.11
12 3.79
Stroke Etiologies With Intravenous Thrombolysis before Thrombectomy and Functional Outcomes in Anterior Circulation Large Vessel Occlusion 0.17
Multimodal Image Guidance in Subthalamic Deep Brain Stimulation for Parkinson's Disease 0.07
Relapses, Comorbidities, and Predictors of Outcome in Anti-GABAA Receptor Encephalitis 0.06
Increased Numbers of CD4+ T-Cells in the Hypocretin/Orexin Region of Narcolepsy Type 1 1.00
Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling 0.04
Aneurysm Wall Enhancement and Probability of Instability in Unruptured Intracranial Aneurysms: A Long‐Term Follow‐Up Study 0.80
Mutations in the Key Autophagy Tethering Factor scpEPG5/scp Link Neurodevelopmental and Neurodegenerative Disorders Including Early‐Onset Parkinsonism 0.05
iHCN2/i‐Associated Neurodevelopmental Disorders: Data from Patients and iXenopus/i Cell Models 0.04
Beta Power Response After Levodopa Intake in Parkinson's Disease Patients With Chronic Sensing‐Enabled Deep Brain Stimulation 1.00
Heart Rate Profiles During Exercise and Incident Parkinson's Disease 0.46
Regional and Global Changes in Brain Structure 1‐Year Post Pediatric “Mild” Traumatic Brain Injury 0.03
Deep Brain Stimulation for scpiVPS16/i/scp‐Related Dystonia: A Multicenter Study 0.06
1 0.25
Efgartigimod in Sjögren’s disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO) 0.25
2 1.03
Surgical Correction of Pes Equinovarus in People With Stroke: Effects on Personalized Goal Attainment and Balance and Gait Capacity 1.00
A Non-Inferiority Randomized Clinical Trial Comparing Three Delivery Formats of a Rehabilitation Intervention to Reduce Fatigue among People with Multiple Sclerosis 0.03
9 3.71
Medial temporal ageing-related tau astrogliopathy below 66 years is associated with neurodegeneration 0.27
Brainstem pathology in anti-IgLON5 disease: new insights into early events and tau progression 0.07
Cortical tau deposition promotes atrophy in connected white matter regions in Alzheimer’s disease 0.06
PU.1 restores microglial dysfunction caused by C9ORF72 repeat expansions in neural organoids 1.00
Parkinson’s disease progression is shaped by longitudinal changes in cerebral compensation 1.00
Brain atrophy patterns in anti-IgLON5 disease 0.13
Amygdalar and hippocampal volume loss in limbic-predominant age-related TDP-43 encephalopathy 0.97
Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan 0.08
Oxygen extraction fraction in small vessel disease: relationship to disease burden and progression 0.13
1 0.83
SCN10A-short gene therapy to restore conduction and protect against malignant cardiac arrhythmias 0.83
1 0.15
Single-cell spatial transcriptomic profiling defines a pathogenic inflammatory niche in chronic active multiple sclerosis lesions 0.15
1 0.04
Risk of stroke, myocardial infarction, coronary intervention, and atrial fibrillation or flutter in individuals experiencing typical migraine aura without headache: a Danish registry-based cohort study 0.04
1 0.08
Long-term fasting-induced parasympathetic and sympathetic autonomic nervous system modulation in a subgroup of the GENESIS study 0.08
1 0.06
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity 0.06
1 0.86
Opt1 imports CoA precursors as glutathione mixed disulfides 0.86
4 0.85
Pathogenic variants in BORCS5 Cause a Spectrum of Neurodevelopmental and Neurodegenerative Disorders with Lysosomal Dysfunction 0.03
Conserved sleep disturbances in FOXP1 syndrome originate from developmental dysregulation of peptidergic signaling 0.77
Biallelic variants in ARHGAP19 cause a progressive inherited motor-predominant neuropathy 0.04
Sensory neuron–expressed FGF13 controls nociceptive signaling in diabetic neuropathy models 0.02
2 0.37
A cascade model of dynamic cerebral autoregulation 0.17
The contribution of age and sex hormones to female neuromuscular function across the adult lifespan 0.20
3 1.18
Cortical microstructure is associated with disease severity and clinical progression in genetic frontotemporal dementia: a GENFI study 0.10
Reward circuit function and treatment outcome following vALIC deep brain stimulation in treatment-resistant depression 1.00
Cell autonomous microglia defects in a stem cell model of frontotemporal dementia tau 0.08
16 5.82
Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality 0.02
Suppression of pathological oscillations with transcranial focused ultrasound in Parkinson’s disease 0.03
Rapid modulation of choice behavior by ultrasound on the human frontal eye fields 0.89
Reduced Ventral Tegmental Area GABA neuron output contributes to hyperactivity in the activity-based anorexia model in female mice 0.96
Aberrant neural activity in the peritumoral cortex underlies the progression of tumor-associated seizures 0.77
Tripotent Lgr5 stem cells in the posterior tongue generate lingual, taste, and salivary gland lineages 0.93
The Genetic Architecture of the Human Corpus Callosum and its Subregions 0.08
Development of [F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology 0.04
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease 0.04
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial 0.14
Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification 0.21
Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson’s disease 0.86
A multicenter longitudinal study of cholinergic subgroups in Parkinson disease 0.23
Convergent mapping of a tremor treatment network 0.18
Control of spatiotemporal activation of organ-specific fibers in the swine vagus nerve by intermittent interferential current stimulation 0.35
Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson’s disease 0.10
1 0.22
Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis 0.22
5 1.61
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration 0.53
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders 0.39
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial 0.06
Pridopidine in early-stage manifest Huntington’s disease: a phase 3 trial 0.57
Shared and disease-specific pathways in frontotemporal dementia and Alzheimer’s and Parkinson’s diseases 0.06
4 1.22
Investigating the methodological foundation of lesion network mapping 0.67
TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS/FTD 0.03
Region-specific drivers of CSF mobility measured with MRI in humans 0.43
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, genotype and sex 0.09
1 0.15
Distinct tau filament folds in human MAPT mutants P301L and P301Tc 0.15
1 0.02
Neurons undergo IFNγ-driven persistent epigenetic shifts and synaptopathy in encephalitis 0.02
1 0.29
Two pairs of CACNA1I (CaV3.3) variants with opposite effects on channel function cause neurodevelopmental disorders of varying severity 0.29
1 0.25
Interdependent Scaling Exponents in the Human Brain 0.25
3 0.16
Cytotoxic T cell recognition of α-synuclein drives pathogenic immune responses in multiple system atrophy 0.02
Immune cell profiling reveals expanded stem cell–like memory T cells in anti-GAD65-associated neurological syndromes 0.09
Stathmin-2 enhances motor axon regeneration after injury independent of its binding to tubulin 0.05
2 1.07
Neurons with granulovacuolar degeneration bodies are resilient to tau-induced protein synthesis impairment 1.00
Neuronal lipofuscinosis caused by Kufs disease/CLN4 DNAJC5 mutations but not by a CSPα/DNAJC5 deficiency 0.07
1 0.12
Loss of PILRA promotes microglial immunometabolism to reduce amyloid pathology in cell and mouse models of Alzheimer’s disease 0.12
2 1.09
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials 0.09
Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial 1.00
2 0.06
Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case–control study 0.02
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial 0.04
1 0.06
The distinctive psychopathology of NMDAR-antibody encephalitis compared with primary psychoses: an international, multicentre, retrospective phenotypic analysis 0.06
2 0.08
Asundexian for Secondary Stroke Prevention 0.04
Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1 0.05

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.